- In October 2024, Boston Scientific has obtained U.S. FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter, designed to treat paroxysmal atrial fibrillation. Additionally, the company has received FDA 510(k) clearance for the new FARAVIEW Software, which will work in conjunction with the FARAPULSE Pulsed Field Ablation System to enhance visualization during cardiac ablation procedures
- In May 2024, Biosense Webster, Inc., a global leader in the treatment of cardiac arrhythmias and a part of Johnson & Johnson MedTech, has announced the launch of the CARTO 3 System Version 8. This latest iteration of the company’s premier three-dimensional (3D) heart mapping system is utilized in cardiac ablation procedures. The updated software includes new modules such as the CARTO ELEVATE Module and the CARTOSOUND FAM Module, which are designed to enhance efficiency, reproducibility, and accuracy for electrophysiologists conducting catheter ablation procedures to treat patients with atrial fibrillation (AFib) and other arrhythmias
- In December 2023, The U.S. Food and Drug Administration (FDA) has granted approval for the PulseSelect Pulsed Field Ablation (PFA) System from Medtronic to treat both paroxysmal and persistent atrial fibrillation (AF), as announced by the manufacturer. This innovative technology utilizes microsecond-scale pulsed electrical fields for pulmonary vein isolation (PVI) to help reduce AF and is the first PFA system to receive FDA approval for this condition
- In May 2023, Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved its TactiFlex Ablation Catheter, Sensor Enabled, marking it as the world's first ablation catheter featuring a flexible tip and contact force technology. Designed for use in ablation procedures to treat atrial fibrillation (AFib), the most prevalent type of abnormal heart rhythm, the TactiFlex catheter is capable of reducing procedure times and enhancing safety compared to the company’s previous generation catheters
- In June 2021, Acutus Medical, an arrhythmia management company dedicated to enhancing the diagnosis and treatment of cardiac arrhythmias, has launched the AcQBlate Force Sensing Ablation System in Europe following the acquisition of CE Mark approval for its AcQBlate FORCE ablation catheter and the Qubic Force Sensing Module (Qubic Force). This system features the AcQBlate Force, the first and only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market
Frequently Asked Questions
The market is segmented based on Global Cardiac Ablation System Market Segmentation, By Product (Radiofrequency (RF) Ablators, Electrical Ablators, Cryoablation Devices, Ultrasound Ablators, and Others), Application (Cardiac Rhythm Management, Open surgery, and Others), End Use (Hospitals, Ambulatory surgical centres, Cardiac centres, and Others) – Industry Trends and Forecast to 2031
.
The Global Cardiac Ablation System Market size was valued at USD 1.18 USD Billion in 2023.
The Global Cardiac Ablation System Market is projected to grow at a CAGR of 12.22% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
